Partnership with Swinburne & Cooper Investors

Swinburne has signed a transformational $1 million agreement with Hearts and Minds Investments Ltd and Cooper Investors supporting vital mental health medical research.

Partnership with Swinburne & Cooper Investors

September 23, 2021
Swinburne has signed a transformational $1 million agreement with Hearts and Minds Investments Ltd and Cooper Investors supporting vital mental health medical research.
Read Transcript

Swinburne’s Centre for Human Psychopharmacology has received a further $1 million in philanthropic funding for their research, which will use the latest neuroimaging technology.

In summary:

  • Swinburne has received a transformational commitment of $1 million from Hearts and Minds Investments Ltd to support key mental health medical research
  • Funding will support programs to boost emotional intelligence (EI) in lower socioeconomic status primary and secondary schools, and explore the connection between the gut microbiome and cognitive decline
  • Researchers from Swinburne’s Centre for Human Psychopharmacology will blend fundamental research with the latest technologies to deliver key advances for mental health

 

Swinburne has signed a new agreement with Hearts and Minds Investments Ltd and Cooper Investors that will see a further $1 million invested into medical research by 2023. This takes the total investment from Hearts and Minds Investments Ltd to $1.7 million.

The gift will support research by Swinburne’s Centre for Human Psychopharmacology into improving emotional intelligence (EI) in schools, as well as the link between gut microbiome and healthy cognitive ageing.

 

Delivering lasting impact

Swinburne’s Centre for Human Psychopharmacology brings together institutions from around the globe and uses the latest technologies and research methodologies to develop new medicine and drive a new generation of medical research in Australia.

The research will apply scientific rigour and the latest technology to research biological determinants of cognitive health across one's lifespan. It will also include trials with Swinburne’s bespoke neuroimaging capability and interactive online research programs for participants.  The research supports Swinburne’s vision of bringing people and technology together to build a better world.

Swinburne’s Vice-Chancellor and President, Professor Pascale Quester, says the benefits of the research, made possible by support from Hearts and Minds and Cooper Investors, will be felt for generations to come.

‘Swinburne is proud to be partnering with Cooper Investors and Hearts and Minds. This investment will support early career researchers and enable them to make real advances in key areas of health and medical research,’ Professor Quester says.

‘Blending human insight and endeavour with technology, this research will help understand how the health of our microbiome affects cognitive decline as we age, and we can explore how to drive school retention and performance through increased emotional intelligence.  It is vital research like this that is helping us achieve our vision of bringing humans and technology together to build a better world.’

 

Investing in our future

Since 2019, the philanthropic partnership between Swinburne and Hearts and Minds has contributed to the overall improvement of mental health, intuition and wellbeing of Australians.

CEO of Hearts and Minds Investments Ltd and Swinburne alum, Paul Rayson, says the organisation has a passion for growing sustainable, progressive partnerships, like the one with Swinburne.

‘Investing in research is investing in our future – a long-term investment into making the world a better place,’ Rayson says.

‘There are many quality of life issues that can be enhanced by a better understanding of human cognition, mood and behaviour. We see the world-class research conducted at Swinburne as having the potential to make a positive impact and lead to improved treatments and management of cognitive health,’ he says.

‘When it comes to medical research, everyone is hoping to get that breakthrough, which can be rare, but when you do get it – it has a huge benefit.’

Cooper Investors, that nominated Swinburne as a beneficiary for Hearts and Minds funds, said: ‘Philanthropy or the act of contribution is a core value at Cooper Investors.’

‘We recognise mental health as the health challenge of a generation and believe that, wherever possible, we should look to support institutions like Swinburne to conduct vital translational research in this area. We want to use our philanthropy program to support world-class research and programs to better the mental health of communities across the country.’

 

 

Swinburne’s Centre for Human Psychopharmacology has received a further $1 million in philanthropic funding for their research, which will use the latest neuroimaging technology.

In summary:

  • Swinburne has received a transformational commitment of $1 million from Hearts and Minds Investments Ltd to support key mental health medical research
  • Funding will support programs to boost emotional intelligence (EI) in lower socioeconomic status primary and secondary schools, and explore the connection between the gut microbiome and cognitive decline
  • Researchers from Swinburne’s Centre for Human Psychopharmacology will blend fundamental research with the latest technologies to deliver key advances for mental health

 

Swinburne has signed a new agreement with Hearts and Minds Investments Ltd and Cooper Investors that will see a further $1 million invested into medical research by 2023. This takes the total investment from Hearts and Minds Investments Ltd to $1.7 million.

The gift will support research by Swinburne’s Centre for Human Psychopharmacology into improving emotional intelligence (EI) in schools, as well as the link between gut microbiome and healthy cognitive ageing.

 

Delivering lasting impact

Swinburne’s Centre for Human Psychopharmacology brings together institutions from around the globe and uses the latest technologies and research methodologies to develop new medicine and drive a new generation of medical research in Australia.

The research will apply scientific rigour and the latest technology to research biological determinants of cognitive health across one's lifespan. It will also include trials with Swinburne’s bespoke neuroimaging capability and interactive online research programs for participants.  The research supports Swinburne’s vision of bringing people and technology together to build a better world.

Swinburne’s Vice-Chancellor and President, Professor Pascale Quester, says the benefits of the research, made possible by support from Hearts and Minds and Cooper Investors, will be felt for generations to come.

‘Swinburne is proud to be partnering with Cooper Investors and Hearts and Minds. This investment will support early career researchers and enable them to make real advances in key areas of health and medical research,’ Professor Quester says.

‘Blending human insight and endeavour with technology, this research will help understand how the health of our microbiome affects cognitive decline as we age, and we can explore how to drive school retention and performance through increased emotional intelligence.  It is vital research like this that is helping us achieve our vision of bringing humans and technology together to build a better world.’

 

Investing in our future

Since 2019, the philanthropic partnership between Swinburne and Hearts and Minds has contributed to the overall improvement of mental health, intuition and wellbeing of Australians.

CEO of Hearts and Minds Investments Ltd and Swinburne alum, Paul Rayson, says the organisation has a passion for growing sustainable, progressive partnerships, like the one with Swinburne.

‘Investing in research is investing in our future – a long-term investment into making the world a better place,’ Rayson says.

‘There are many quality of life issues that can be enhanced by a better understanding of human cognition, mood and behaviour. We see the world-class research conducted at Swinburne as having the potential to make a positive impact and lead to improved treatments and management of cognitive health,’ he says.

‘When it comes to medical research, everyone is hoping to get that breakthrough, which can be rare, but when you do get it – it has a huge benefit.’

Cooper Investors, that nominated Swinburne as a beneficiary for Hearts and Minds funds, said: ‘Philanthropy or the act of contribution is a core value at Cooper Investors.’

‘We recognise mental health as the health challenge of a generation and believe that, wherever possible, we should look to support institutions like Swinburne to conduct vital translational research in this area. We want to use our philanthropy program to support world-class research and programs to better the mental health of communities across the country.’

 

 

Disclaimer: This material has been prepared by Swinburne's Centre For Human Psychopharmacology, published on Sep 23, 2021. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
December 5, 2023

Prof Daniel MacArthur | Sohn Hearts & Minds Conference

At this year's Sohn Hearts & Minds Conference, we heard from Prof Daniel MacArthur, the Director of the Centre for Population Genomics.

Read More
December 5, 2023

Prof Michelle Simmons AO | Sohn Hearts & Minds Conference

At this year's Sohn Hearts & Minds Conference, we heard from Prof Michelle Simmons, the CEO and Founder of Silicon Quantum Computing.

Read More
December 5, 2023

Prof Misty Jenkins AO | Sohn Hearts & Minds Conference

At this year's Sohn Hearts & Minds Conference, we heard from Prof Misty Jenkins. Misty is a NHMRC fellow and laboratory head of the Immunology Division at the Walter and Eliza Hall Institute.

Read More
December 4, 2023

Is dementia truly preventable?

In this NeuRA Talk, Professor Kaarin Anstey, Dr Nikki-Anne Wilson and Dr Bill Brooks are joined by Executive Director of Professional Services, Carole Renouf to answer the question: Is dementia truly preventable?

Read More
November 10, 2023

Big thinkers in hunt for brain cancer cure

“Brain cancer is rare, but for people who do get it the prognosis is not good,” Assistant Professor Jenkins tells The Australian.

Read More
November 6, 2023

Genomic medicine the future of health?

DNA sequences may well hold the secrets to better health. Profound changes in the practice of medicine are underway, being driven by rapid developments in several fields, particularly in genomics.

Read More
October 3, 2023

WA scientists win Hearts and Minds

We’re excited to announce that we have made our first donation to a beneficiary in Western Australia, Harry Perkins Institute of Medical Research.

Read More
Left to right: Mike Lawrence, Nicholas Kirk and Mai MargettsLeft to right: Mike Lawrence, Nicholas Kirk and Mai MargettsLeft to right: Mike Lawrence, Nicholas Kirk and Mai MargettsLeft to right: Mike Lawrence, Nicholas Kirk and Mai Margetts
July 14, 2023

Could insulin come in a pill? How a molecule that mimics insulin may advance diabetes research

WEHI researchers have answered a 100-year-old question in diabetes research: can a molecule different to insulin have the same effect?

Read More
May 8, 2023

The Florey. Where remarkable minds advance brain research.

The Florey is the home of neuroscience and mental health research, advancing knowledge of the brain to improve health outcomes for us all. Learn more about their organisation here.

Read More
May 5, 2023

Medicare Heart Health Check Saved

The Victor Chang Cardiac Research Institute says that the Federal Government's decision to extend Medicare-funded Heart Health Checks will save lives.

Read More
Merilyn Oakes and Professor Michael Feneley. Picture: John FederMerilyn Oakes and Professor Michael Feneley. Picture: John FederMerilyn Oakes and Professor Michael Feneley. Picture: John FederMerilyn Oakes and Professor Michael Feneley. Picture: John Feder
April 20, 2023

Artificial intelligence gives new hope for sufferers of severe heart problem

New AI software can improve the diagnosis of severe aortic stenosis by 72% and could potentially change the lives of about 50,000 Australians with the life-threatening condition.

Read More
April 20, 2023

Innovation Centre's key role in delivering new stroke treatments

The Innovation Centre at the Victor Chang Cardiac Research Institute has been very useful for Dr Kirsten Coupland from the University of Newcastle to help her shed light on the inner workings of the brain.

Read More
April 13, 2023

Saving Hearts to Save Lives

Professor Peter Macdonald from the Victor Chang Cardiac Research Institute opens up about his career as a cardiologist and scientist, the groundbreaking 'Heart in a Box', and the potential of deadly spider venom.

Read More
March 7, 2023

Case Study Highlight: The Baker Heart & Diabetes Institute

Working closely with Indigenous communities, The Baker Heart and Diabetes Institute is working to help tackle heart disease and diabetes in remote communities of Central Australia.

Read More
February 21, 2023

A Heart in a Box: The Gift of Life

A “heart in a box”. It sounds like an ad for Valentine’s Day chocolates. But this box contains an actual human heart which is pumping outside its original body, enabling the gift of life from one person to another.

Read More